Progress of research on mesenchymal transformation of renal resident cells in the chronicity of lupus nephritis

doi:10.3877/cma.j.issn.2095-3216.2022.06.009

Abstract

Abstract:

Renal fibrosis in lupus nephritis (LN) seriously affects the prognosis of patients with systemic lupus erythematosus (SLE). Mesenchymal transition of renal intrinsic cells plays a key role in the development of LN fibrosis. Mesenchymal transition of renal intrinsic cells can promote the repair of tissue damage in the early stage, but it is also a key way to lead the diseased kidney into fibrosis in the late stage. As the mesenchymal transition of renal intrinsic cells is a reversible process, it provides a valuable time window for early anti-fibrosis treatment. This article reviewed the latest research on mesenchymal transition of renal intrinsic cells in LN.

Key words: Lupus nephritis, Mesenchymal transition, Fibrosis, Pathogenesis

Jiaming Huang, Hongxia Duan, Yupeng Lai, Daji Wang, Xingjiao Liu, Xin Shen, Meiying Wang. Progress of research on mesenchymal transformation of renal resident cells in the chronicity of lupus nephritis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(06): 347-352.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2022.06.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2022/V11/I06/347

Figures/Tables 2

References 46

[1]	Yen EY, Shaheen M, Woo JMP, et al. 46-Year Trends in systemic lupus erythematosus mortality in the United States, 1968 to 2013: a nationwide population-based study [J]. Ann Intern Med, 2017, 167(11): 777-785.
[2]	Zucchi D, Elefante E, Schiliro D, et al. One year in review 2022: systemic lupus erythematosus [J]. Clin Exp Rheumatol, 2022, 40(1): 4-14.
[3]	Ovadya Y, Krizhanovsky V. A new twist in kidney fibrosis [J]. Nat Med, 2015, 21(9): 975-977.
[4]	LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis [J]. Nat Med, 2013, 19(8): 1047-1053.
[5]	Yuan Q, Tan RJ, Liu Y. Myofibroblast in kidney fibrosis: origin, activation, and regulation [J]. Adv Exp Med Biol, 2019, 1165: 253-283.
[6]	Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms [J]. Nat Rev Nephrol, 2022, 18(9): 545-557.
[7]	Sheng L, Zhuang S. New insights into the role and mechanism of partial epithelial-mesenchymal transition in kidney fibrosis [J]. Front Physiol, 2020, 11: 569322.
[8]	Fu D, Senouthai S, Wang J, et al. FKN facilitates HK-2 cell EMT and tubulointerstitial lesions via the Wnt/β-catenin pathway in a murine model of lupus nephritis [J]. Front Immunol, 2019, 10: 784.
[9]	Liu Q, Du Y, Li K, et al. Anti-OSM antibody inhibits tubulointerstitial lesion in a murine model of lupus nephritis [J]. Mediators Inflamm, 2017, 2017: 3038514.
[10]	Markwald RR, Fitzharris TP, Smith WN. Sturctural analysis of endocardial cytodifferentiation [J]. Dev Biol, 1975, 42(1): 160-180.
[11]	Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition [J]. J Am Soc Nephrol, 2008, 19(12): 2282-2287.
[12]	Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice [J]. Am J Pathol, 2009, 175(4): 1380-1388.
[13]	周颖，陈樱花，张明超，等. 系统性红斑狼疮相关血栓性微血管病血管内皮-间充质细胞转分化的研究[J]. 肾脏病与透析肾移植杂志，2017, 26(1): 20-25.
[14]	Loeffler I, Wolf G. Epithelial-to-mesenchymal transition in diabetic nephropathy: fact or fiction? [J]. Cells, 2015, 4(4): 631-652.
[15]	Sam R, Wanna L, Gudehithlu KP, et al. Glomerular epithelial cells transform to myofibroblasts: early but not late removal of TGF-beta(1) reverses transformation [J]. Transl Res, 2006, 148(3): 142-148.
[16]	Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition [J]. Sci Signal, 2014, 7(344): re8.
[17]	Cruz-Solbes AS, Youker K. Epithelial to mesenchymal transition (EMT) and endothelial to mesenchymal transition (EndMT): role and implications in kidney fibrosis [J]. Results Probl Cell Differ, 2017, 60: 345-372.
[18]	Meng XM, Tang PM, Li J, et al. TGF-beta/Smad signaling in renal fibrosis [J]. Front Physiol, 2015, 6: 82.
[19]	Zhang YE. Non-Smad signaling pathways of the TGF-beta family [J]. Cold Spring Harb Perspect Biol, 2017; 9(2): a022129.
[20]	Patel S, Takagi KI, Suzuki J, et al. RhoGTPase activation is a key step in renal epithelial mesenchymal transdifferentiation [J]. J Am Soc Nephrol, 2005, 16(7): 1977-1984.
[21]	Das S, Becker BN, Hoffmann FM, et al. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway [J]. BMC Cell Biol, 2009, 10: 94.
[22]	Zavadil J, Cermak L, Soto-Nieves N, et al. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition [J]. EMBO J, 2004, 23(5): 1155-1165.
[23]	Tan RJ, Zhou D, Zhou L, et al. Wnt/beta-catenin signaling and kidney fibrosis [J]. Kidney Int Suppl (2011), 2014, 4(1): 84-90.
[24]	Wong DWL, Yiu WH, Chan KW, et al. Activated renal tubular Wnt/β-catenin signaling triggers renal inflammation during overload proteinuria [J]. Kidney Int, 2018, 93(6): 1367-1383.
[25]	Singh SP, Tao S, Fields TA, et al. Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice [J]. Dis Model Mech, 2015, 8(8): 931-940.
[26]	Nyhan KC, Faherty N, Murray G, et al. Jagged/Notch signalling is required for a subset of TGF β1 responses in human kidney epithelial cells [J]. Biochim Biophys Acta, 2010, 1803(12): 1386-1395.
[27]	Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease [J]. Cells Tissues Organs, 2007, 185(1-3): 222-231.
[28]	Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis [J]. Nat Med, 2015, 21(9): 998-1009.
[29]	Grande MT, Sanchez-Laorden B, Lopez-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease [J]. Nat Med, 2015, 21(9): 989-997.
[30]	Platel V, Faure S, Corre I, et al. Endothelial-to-mesenchymal transition (EndoMT): roles in tumorigenesis, metastatic extravasation and therapy resistance [J]. J Oncol, 2019, 2019: 8361945.
[31]	Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis [J]. Am J Pathol, 2011, 179(5): 2660-2673.
[32]	Zhou J, Li R, Liu Q, et al. Blocking 5-LO pathway alleviates renal fibrosis by inhibiting the epithelial-mesenchymal transition [J]. Biomed Pharmacother, 2021, 138: 111470.
[33]	Yung S, Tsang RC, Sun Y, et al. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis [J]. J Am Soc Nephrol, 2005, 16(11): 3281-3294.
[34]	Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis [J]. Am J Pathol, 2001, 159(4): 1465-1475.
[35]	Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis [J]. J Am Soc Nephrol, 2011, 22(7): 1262-1274.
[36]	Kinloch AJ, Chang A, Ko K, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis [J]. Arthritis Rheumatol, 2014, 66(12): 3359-3370.
[37]	Pieterse E, Rother N, Garsen M, et al. Neutrophil extracellular traps drive endothelial-to-mesenchymal transition [J]. Arterioscler Thromb Vasc Biol, 2017, 37(7): 1371-1379.
[38]	Zhang L, Liu L, Bai M, et al. Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-κB [J]. FASEB J, 2020, 34(2): 2554-2567.
[39]	Fairhurst AM, Xie C, Fu Y, et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis [J]. J Immunol, 2009, 183(10): 6831-6838.
[40]	Ding X, Ren Y, He X. IFN-I mediates lupus nephritis from the beginning to renal fibrosis [J]. Front Immunol, 2021, 12: 676082.
[41]	Shi S, Srivastava SP, Kanasaki M, et al. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition [J]. Kidney Int, 2015, 88(3): 479-489.
[42]	Chen Y, Zou H, Lu H, et al. Research progress of endothelial-mesenchymal transition in diabetic kidney disease [J]. J Cell Mol Med, 2022, 26(12): 3313-3322.
[43]	Liang D, Liu S, Song Z, et al. Metformin ameliorates renal fibrosis in mice with unilateral ureteral obstruction and inhibits TGF-β1-induced upregulation of cadherin-6 in renal proximal tubule epithelial cells [J]. Diabetes, 2018, 67(Suppl 1): 2199-PUB.
[44]	Liu X, Sun N, Mo N, et al. Quercetin inhibits kidney fibrosis and the epithelial to mesenchymal transition of the renal tubular system involving suppression of the Sonic Hedgehog signaling pathway [J]. Food Funct, 2019, 10(6): 3782-3797.
[45]	Grande MT, Sánchez-Laorden B, López-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease [J]. Nat Med, 2015, 21(9): 989-997.
[46]	Ruiz-Ortega M, Lamas S, Ortiz A. Antifibrotic agents for the management of CKD: a review [J]. Am J Kidney Dis, 2022, 80(2): 251-263.

研究状态	药物
临床可用	RAS阻滞剂；Finerenonea (MRA)；卡格列净、达格列净(SGLT2抑制剂);己酮可可碱(非选择性磷酸二酯酶抑制剂)
正在进行的肾脏保护药物临床试验	吡非尼酮(调控信使RNA); Lademirsen (miR-21 antagomir)
具有肾脏保护的临床前证据，正在进行肺纤维化临床试验	Nintedanib(酪氨酸激酶抑制剂)；PRM-151(重组人五聚蛋白2/血清淀粉样蛋白P蛋白)；表没食子儿茶素没食子酸酯(赖氨酰氧化酶样2和TGF-β受体1和2激酶抑制剂); Ziritaxestat(自体趋化因子抑制剂)
前期研究中确定的肾纤维化关键药物和治疗靶点	曲美替尼(MEK抑制剂)；抗IL-11抗体；NKD2；能量感应和线粒体功能调节剂
目前暂停或放弃的肾纤维化临床开发	Fresolimumab，LY2382770(抗TGF-β1抗体) FG-3019(pamrevlumab；抗CCN2抗体) STX-100(BG00011；抗整合素α5β6抗体[αvβ6激活TGF-β]) GCS-100(半乳糖凝集素3拮抗剂)

研究状态	药物
临床可用	RAS阻滞剂；Finerenonea (MRA)；卡格列净、达格列净(SGLT2抑制剂);己酮可可碱(非选择性磷酸二酯酶抑制剂)
正在进行的肾脏保护药物临床试验	吡非尼酮(调控信使RNA); Lademirsen (miR-21 antagomir)
具有肾脏保护的临床前证据，正在进行肺纤维化临床试验	Nintedanib(酪氨酸激酶抑制剂)；PRM-151(重组人五聚蛋白2/血清淀粉样蛋白P蛋白)；表没食子儿茶素没食子酸酯(赖氨酰氧化酶样2和TGF-β受体1和2激酶抑制剂); Ziritaxestat(自体趋化因子抑制剂)
前期研究中确定的肾纤维化关键药物和治疗靶点	曲美替尼(MEK抑制剂)；抗IL-11抗体；NKD2；能量感应和线粒体功能调节剂
目前暂停或放弃的肾纤维化临床开发	Fresolimumab，LY2382770(抗TGF-β1抗体) FG-3019(pamrevlumab；抗CCN2抗体) STX-100(BG00011；抗整合素α5β6抗体[αvβ6激活TGF-β]) GCS-100(半乳糖凝集素3拮抗剂)

Please choose a citation manager

Content to export